Skip to main content
. 2017 Apr 25;8(28):45807–45824. doi: 10.18632/oncotarget.17416

Figure 2.

Figure 2

(A) MiR-107, (B) miR-122, and (C) miR-195 expression in NSCLC patients with different EGFR-sensitive mutations. *EGFR exon 19 deletion (19DEL) vs. EGFR wild-type (WT) patients (fold-change: miR-107, 7.44 and miR-195, 3.25; p < 0.05). #EGFR p.L858R mutation vs. EGFRWT patients (fold-change: miR-107, 5.22 and miR-122, 11.29; p < 0.05). *EGFR mutation-positive (MUT[+]) vs. EGFRWT patients (fold-change: miR-107, 6.64 and miR-122, 6.41; p < 0.05).